Atle Fund Management AB Has $2.85 Million Stake in NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Atle Fund Management AB increased its holdings in NewAmsterdam Pharma by 45.9%, owning 157,223 shares valued at approximately $2.85 million, making it the 27th largest position in their investment portfolio.
• Insider trading activity included the sale of 50,000 shares by insider Johannes Jacob Piete Kastelein, reducing their ownership by 29.53%, while Director James N. Topper increased their position by acquiring 2,520 shares.
• NewAmsterdam Pharma's latest earnings report showed a significant revenue of $19.15 million with an EPS of ($0.15), surpassing analyst expectations, despite a high negative net margin of 259.07%.

Atle Fund Management AB raised its position in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 45.9% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 157,223 shares of the company's stock after purchasing an additional 49,440 shares during the period. NewAmsterdam Pharma accounts for approximately 1.2% of Atle Fund Management AB's holdings, making the stock its 27th biggest position. Atle Fund Management AB owned approximately 0.14% of NewAmsterdam Pharma worth $2,847,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of NAMS. PTM Wealth Management LLC bought a new stake in shares of NewAmsterdam Pharma during the second quarter valued at approximately $256,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in NewAmsterdam Pharma by 13.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company's stock valued at $5,898,000 after acquiring an additional 34,563 shares in the last quarter. Woodline Partners LP raised its stake in NewAmsterdam Pharma by 0.5% during the 1st quarter. Woodline Partners LP now owns 2,442,397 shares of the company's stock valued at $49,996,000 after acquiring an additional 11,615 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in NewAmsterdam Pharma by 32.6% during the 1st quarter. Parkman Healthcare Partners LLC now owns 100,955 shares of the company's stock worth $2,067,000 after acquiring an additional 24,839 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of NewAmsterdam Pharma in the first quarter worth $610,000. Institutional investors own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider directly owned 119,302 shares of the company's stock, valued at $2,897,845.58. This represents a 29.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James N. Topper purchased 1,260 shares of NewAmsterdam Pharma stock in a transaction dated Monday, September 8th. The shares were purchased at an average price of $24.99 per share, with a total value of $31,487.40. Following the completion of the acquisition, the director owned 3,027,864 shares in the company, valued at $75,666,321.36. The trade was a 0.04% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 3,651 shares of company stock worth $81,432 and have sold 324,954 shares worth $7,844,906. 20.84% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on NAMS shares. Wells Fargo & Company started coverage on shares of NewAmsterdam Pharma in a report on Monday, August 25th. They issued an "overweight" rating and a $45.00 price objective for the company. Citigroup began coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 17th. They set a "buy" rating and a $42.00 price target on the stock. Stifel Nicolaus initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of NewAmsterdam Pharma in a research note on Thursday, July 17th. They set a "neutral" rating and a $27.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Eight analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $42.00.

NewAmsterdam Pharma Price Performance

NAMS traded down $0.41 on Tuesday, reaching $26.65. 268,258 shares of the company traded hands, compared to its average volume of 888,586. The company has a market cap of $3.00 billion, a price-to-earnings ratio of -16.44 and a beta of -0.01. The stock's 50 day moving average price is $24.20 and its 200-day moving average price is $20.96. NewAmsterdam Pharma Company N.V. has a 52-week low of $14.06 and a 52-week high of $27.35.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The company had revenue of $19.15 million during the quarter, compared to analyst estimates of $1.44 million. As a group, equities research analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.